Lecanemab for Alzheimer’s disease
Open accessAbstract
New trial reports little to celebrate for patients and carers
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Infusion-related reactions occur in about 26% of patients on lecanemab and 7.4% of patients on placebo.
“infusion-related reactions, in about 26% of patients on lecanemab, and only 7.4% of patients on placebo. (507) (460, 461)”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [507]
In the US, Medicare and CMS will provide usual coverage for lecanemab and donanemab if physicians enter patients' data into a CMS-facilitated registry.
“In the US, Medicare and CMS will provide usual coverage or lecanemab and donanemab, if physicians enter patients' data into a CMS -facilitated registry. (514)”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [514]
No citation lists for this paper
No citation lists for this paper yet — checked again daily.
References 12 · Cited by 76
- Authors
- Walsh, S., Merrick, R., Richard, E., Nurock, S., & Brayne, C.
- Affiliations
- University of Cambridge (GB)
- Radboud University Medical Center (NL)
- Corresponding author
- Walsh, Sebastian
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2022-12-19
- Volume
- 379
- Pages
- o3010
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W4311894850
- Cited by
- 76
- References
- 12
- Citations by year
- 2026: 9 · 2025: 18 · 2024: 21 · 2023: 28
- Type
- journal article
- Language
- en
- Open access
- green
- pure.amc.nl
- Licence
- Locations
- BMJ (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion, cc-by)
- Radboud Repository (Radboud University) (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- National Institute for Health and Care Research (NF-SI-0616-10090, NIHR302276, NF-SI-0611-10084)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
- Keywords
- lecanemab, Alzheimer's disease, anti-amyloid therapy, clinical trial results, caregivers, amyloid-beta
- MeSH terms
- Alzheimer Disease, Humans, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
